# Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery

> **NCT01229202** · PHASE4 · WITHDRAWN · sponsor: **Nova Scotia Health Authority**

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01229202
- **Lead sponsor:** Nova Scotia Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** 2012-12
- **Final completion:** 2016-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No REB file
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229202, "Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01229202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*